Detail of the clinical trial
| Title of the trial | An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer |
|---|---|
| EudraCT number | 2018-004211-42 |
| Protocol number | POL6326-009 |
| Sponsor | Polyphor Ltd., Hegenheimermattweg 125, Allschwil, CH-4123, Switzerland |
| Indications | Oncology |
| Diagnosis | metastatic breast cancer |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2019 |
| Date of approval by Institute (SÚKL) | 6.3.2020 |
| Date of approval by EC | |
| Date of initiation CT in ČR | 17.6.2020 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Fakultní nemocnice Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581, Hradec Králové,500 05 Fakultní nemocnice v Motole ,Onkologická klinika,V Úvalu 84,Praha 5,150 06 Multiscan s.r.o.,Ambulance klinické onkologie, K Nemocnici 1106/14,Hořovice,268 31 Thomayerova nemocnice,Onkologická klinika 1. LF UK a TN,Vídeňská 800,Praha 4,140 59 |
cz